Early infection with Leishmania major restrains pathogenic response to Leishmania amazonensis and parasite growth

Acta Tropica

Volumn 106, Issue 1, 2008, Pages 27-38

  Gonzalez Lombana C Z ^a   Santiago, H C ^a   Macedo, J P ^a   Seixas, V A R ^a   Russo, R C ^a   Tafuri, W L ^a   Afonso, L C C ^b   Vieira, L Q ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

Cellular recruitment; Co infection; Cutaneous leishmaniasis; Protozoan parasites

Indexed keywords

GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; RANTES;

GROWTH; IMMUNITY; INFECTIOUS DISEASE; NITRIC OXIDE; PARASITE; PATHOGEN; PROTOZOAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DOWN REGULATION; INFLAMMATORY INFILTRATE; LEISHMANIA; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPHOCYTE; MIXED INFECTION; MONOCYTE; MOUSE; NONHUMAN; PARASITE IMMUNITY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

ANIMALS; CHEMOKINE CCL3; CHEMOKINE CCL5; FEMALE; FOOT; INTERFERON TYPE II; INTERLEUKIN-10; LEISHMANIA; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR-ALPHA;

LEISHMANIA AMAZONENSIS; LEISHMANIA MAJOR; MUS; PROTOZOA;

EID: 40849139007     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2007.12.012     Document Type: Article

References (63)

1. Afonso L.C.C., and Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect. Immun. 61 (1993) 2952-2959
2. Alexander J. A radioattenuated Leishmania major vaccine markedly increases the resistance of CBA mice to subsequent infection with Leishmania mexicana mexicana. Trans. R. Soc. Trop. Med. Hyg. 76 (1982) 646-649
3. Alexander J., and Kaye P.M. Immunoregulatory pathways in murine leishmaniasis: different regulatory control during Leishmania mexicana mexicana and Leishmania major infections. Clin. Exp. Immunol. 61 (1985) 674-682
4. Alexander J., and Phillips R.S. Leishmania tropica and Leishmania mexicana: cross-immunity in mice. Exp. Parasitol. 45 (1978) 93-100
5. Alexander J., and Phillips R.S. Leishmania mexicana and Leishmania tropica major: adoptive transfer of immunity in mice. Exp. Parasitol. 49 (1980) 34-40
6. Aliberti J.C., Machado F.S., Souto J.T., Campanelli A.P., Teixeira M.M., Gazzinelli R.T., and Silva J.S. beta-Chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi. Infect. Immun. 67 (1999) 4819-4826
7. Anderson C.F., Mendez S., and Sacks D.L. Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL/6 mice. J. Immunol. 174 (2005) 2934-2941
8. Anderson C.F., Oukka M., Kuchroo V.J., and Sacks D. CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 204 (2007) 285-297
9. Arnoldi J., and Moll H. Langerhans cell migration in murine cutaneous leishmaniasis: regulation by tumor necrosis factor alpha, interleukin-1 beta, and macrophage inflammatory protein-1 alpha. Dev. Immunol. 6 (1998) 3-11
10. Barral A., Badaro R., Barral-Netto M., Grimaldi Jr. G., Momem H., and Carvalho E.M. Isolation of Leishmania mexicana amazonensis from the bone marrow in a case of American visceral leishmaniasis. Am. J. Trop. Med. Hyg. 35 (1986) 732-734
11. Barral A., Petersen E.A., Sacks D.L., and Neva F.A. Late metastatic leishmaniasis in the mouse. A model for mucocutaneous disease. Am. J. Trop. Med. Hyg. 32 (1983) 277-285
12. Barral-Netto M., Barral A., Brownell C.E., Skeiky Y.A., Ellingsworth L.R., Twardzik D.R., and Reed S.G. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257 (1992) 545-548
13. Belkaid Y., Hoffmann K.F., Mendez S., Kamhawi S., Udey M.C., Wynn T.A., and Sacks D.L. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194 (2001) 1497-1506
14. Bhattacharyya S., Ghosh S., Dasgupta B., Mazumder D., Roy S., and Majumdar S. Chemokine-induced leishmanicidal activity in murine macrophages via the generation of nitric oxide. J. Infect. Dis. 185 (2002) 1704-1708
15. Buxbaum L.U., and Scott P. Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions. Infect. Immun. 73 (2005) 2101-2108
16. Calabrese K.S., and da Costa S.C. Enhancement of Leishmania amazonensis infection in BCG non-responder mice by BCG-antigen specific vaccine. Mem. Inst. Oswaldo Cruz 87 Suppl. 1 (1992) 49-56
17. Coelho E.A., Tavares C.A., Carvalho F.A., Chaves K.F., Teixeira K.N., Rodrigues R.C., Charest H., Matlashewski G., Gazzinelli R.T., and Fernandes A.P. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect. Immun. 71 (2003) 3988-3994
18. Cummings K.L., and Tarleton R.L. Inducible nitric oxide synthase is not essential for control of Trypanosoma cruzi infection in mice. Infect. Immun. 72 (2004) 4081-4089
19. Dasgupta B., Roychoudhury K., Ganguly S., Akbar M.A., Das P., and Roy S. Infection of human mononuclear phagocytes and macrophage-like THP1 cells with Leishmania donovani results in modulation of expression of a subset of chemokines and a chemokine receptor. Scand. J. Immunol. 57 (2003) 366-374
20. De Rossell R.A., Bray R.S., and Alexander J. The correlation between delayed hypersensitivity, lymphocyte activation and protective immunity in experimental murine leishmaniasis. Parasite Immunol. 9 (1987) 105-115
21. Dondji B., Perez-Jimenez E., Goldsmith-Pestana K., Esteban M., and Mahon-Pratt D. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect. Immun. 73 (2005) 5286-5289
22. Fiorentino D.F., Slotnik A., Mosmann T.R., Howard M., and O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147 (1991) 3815-3822
23. Gazzinelli R.T., Oswald I.P., James S.L., and Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. J. Immunol. 148 (1992) 1792-1796
24. Giulietti A., Overbergh L., Valckx D., Decallonne B., Bouillon R., and Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25 (2001) 386-401
25. Gomes I.N., Calabrich A.F., Tavares R.S., Wietzerbin J., De Freitas L.A., and Veras P.S. Differential properties of CBA/J mononuclear phagocytes recovered from an inflammatory site and probed with two different species of Leishmania. Microbes Infect. 5 (2003) 251-260
26. Green S.J., Crawford R.M., Hockmeyer J.T., Meltzer M.S., and Nacy C.A. Leishmania major amastigotes initiate the l-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J. Immunol. 145 (1990) 4290-4297
27. Hernandez M.X., Barcante T.A., Vilela L., Tafuri W.L., Afonso L.C., and Vieira L.Q. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40. Immunol. Lett. 105 (2006) 38-47
28. Hogaboam C.M., Chensue S.W., Steinhauser M.L., Huffnagle G.B., Lukacs N.W., Strieter R.M., and Kunkel S.L. Alteration of the cytokine phenotype in an experimental lung granuloma model by inhibiting nitric oxide. J. Immunol. 159 (1997) 5585-5593
29. Ji J., Masterson J., Sun J., and Soong L. CD4+CD25+ regulatory T cells restrain pathogenic responses during Leishmania amazonensis infection. J. Immunol. 174 (2005) 7147-7153
30. Ji J., Sun J., and Soong L. Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis. Infect. Immun. 71 (2003) 4278-4288
31. Jones D., Elloso M.M., Showe L., Williams D., Trinchieri G., and Scott P. Differential regulation of the interleukin-12 receptor during the innate immune response to Leishmania major. Infect. Immun. 66 (1998) 3818-3824
32. Jones D.E., Ackermann M.R., Wille U., Hunter C.A., and Scott P. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect. Immun. 70 (2002) 2151-2158
33. Jones D.E., Buxbaum L.U., and Scott P. IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J. Immunol. 165 (2000) 364-372
34. Kane M.M., and Mosser D.M. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166 (2001) 1141-1147
35. Khamesipour A., Dowlati Y., Asilian A., Hashemi-Fesharki R., Javadi A., Noazin S., and Modabber F. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23 (2005) 3642-3648
36. Lemos de Souza V., Ascencao Souza J., Correia Silva T.M., Sampaio Tavares Veras P., and Rodrigues de-Freitas L.A. Different Leishmania species determine distinct profiles of immune and histopathological responses in CBA mice. Microbes Infect. 2 (2000) 1807-1815
37. Lukacs N.W., Kunkel S.L., Strieter R.M., Warmington K., and Chensue S.W. The role of macrophage inflammatory protein 1 alpha in Schistosoma mansoni egg-induced granulomatous inflammation. J. Exp. Med. 177 (1993) 1551-1559
38. Lowry O.H., Osebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
39. Mendez S., Reckling S.K., Piccirillo C.A., Sacks D., and Belkaid Y. Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J. Exp. Med. 200 (2004) 201-210
40. Mukbel R., Petersen C.A., and Jones D.E. Soluble factors from Leishmania major-specific CD4+ T cells and B cells limit L. amazonensis amastigote survival within infected macrophages. Microbes Infect. 8 (2006) 2547-2555
41. Mukbel R.M., Patten Jr. C., Gibson K.A.T.H., Ghosh M.O.U.S., Petersen C.H.R.I., and Jones D.E. Macrophage killing of Leishmania amazonensis amastigotes requires both nitric oxide and superoxide. Am. J. Trop. Med. Hyg. 76 (2007) 669-675
42. Muzio M., Bosisio D., Polentarutti N., D'amico G., Stoppacciaro A., Mancinelli R., van't Veer C., Penton-Rol G., Ruco L.P., Allavena P., and Mantovani A. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic Cells. J. Immunol. 164 (2000) 5998-6004
43. Racoosin E.L., and Beverley S.M. Leishmania major: promastigotes induce expression of a subset of chemokine genes in murine macrophages. Exp. Parasitol. 85 (1997) 283-295
44. Ramer A.E., Vanloubbeeck Y.F., and Jones D.E. Antigen-responsive CD4+ T cells from C3H mice chronically infected with Leishmania amazonensis are impaired in the transition to an effector phenotype. Infect. Immun. 74 (2006) 1547-1554
45. Ramos-Santos C., Hernandez-Montes O., Sanchez-Tejeda G., and Monroy-Ostria A. Visceral leishmaniosis caused by Leishmania (L.) mexicana in a Mexican patient with human immunodeficiency virus infection. Mem. Inst. Oswaldo Cruz 95 (2000) 733-738
46. Ritter U., and Korner H. Divergent expression of inflammatory dermal chemokines in cutaneous leishmaniasis. Parasite Immunol. 24 (2002) 295-301
47. Ritter U., and Moll H. Monocyte chemotactic protein-1 stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFN-gamma and is antagonized by IL-4. Eur. J. Immunol. 30 (2000) 3111-3120
48. Ritter U., Moll H., Laskay T., Brocker E., Velazco O., Becker I., and Gillitzer R. Differential expression of chemokines in patients with localized and diffuse cutaneous American leishmaniasis. J. Infect. Dis. 173 (1996) 699-709
49. Rocha P.N., Almeida R.P., Bacellar O., de Jesus A.R., Filho D.C., Filho A.C., Barral A., Coffman R.L., and Carvalho E.M. Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis. J. Infect. Dis. 180 (1999) 1731-1734
50. Santiago H.C., Oliveira C.F., Santiago L., Ferraz F.O., de Souza D.G., De Freitas L.A., Afonso L.C., Teixeira M.M., Gazzinelli R.T., and Vieira L.Q. Involvement of the chemokine RANTES (CCL5) in resistance to experimental infection with Leishmania major. Infect. Immun. 72 (2004) 4918-4923
51. Scharton T.M., and Scott P. Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J. Exp. Med. 178 (1993) 567-577
52. Soong L., Xu J.C., Grewal I.S., Kima P., Sun J., Longley B.J., Ruddle N.H., Mahon-Pratt D., and Flavell R.A. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4 (1996) 263-273
53. Spath G.F., and Beverley S.M. A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp. Parasitol. 99 (2001) 97-103
54. Steigerwald M., and Moll H. Leishmania major modulates chemokine and chemokine receptor expression by dendritic cells and affects their migratory capacity. Infect. Immun. 73 (2005) 2564-2567
55. Stenger S., Donhauser N., Thuring H., Rollinghoff M., and Bogdan C. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. 183 (1996) 1501-1514
56. Uzonna J.E., Spath G.F., Beverley S.M., and Scott P. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol. 172 (2004) 3793-3797
57. Uzonna J.E., Wei G., Yurkowski D., and Bretscher P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J. Immunol. 167 (2001) 6967-6974
58. Vanloubbeeck Y., Ackermann M.R., and Jones D.E. Late cutaneous metastases in C3H SCID mice infected with Leishmania amazonensis. J. Parasitol. 91 (2005) 226-228
59. Vanloubbeeck Y., and Jones D.E. Protection of C3HeB/FeJ mice against Leishmania amazonensis challenge after previous Leishmania major infection. Am. J. Trop. Med. Hyg. 71 (2004) 407-411
60. Vasquez R.E., and Soong L. CXCL10/gamma interferon-inducible protein 10-mediated protection against Leishmania amazonensis infection in mice. Infect. Immun. 74 (2006) 6769-6777
61. Veras P., Brodskyn C., Balestieri F., Freitas L., Ramos A., Queiroz A., Barral A., Beverley S., and Barral-Netto M. A dhfr-ts-Leishmania major knockout mutant cross-protects against Leishmania amazonensis. Mem. Inst. Oswaldo Cruz 94 (1999) 491-496
62. Vieira L.Q., Goldschmidt M., Nashleanas M., Pfeffer K., Mak T., and Scott P. Mice lacking the TNF receptor p55 fail to resolve lesions caused by infection with Leishmania major, but control parasite replication. J. Immunol. 157 (1996) 827-835
63. Zaph C., and Scott P. Interleukin-12 regulates chemokine gene expression during the early immune response to Leishmania major. Infect. Immun. 71 (2003) 1587-1589